Delivery Order SPE2DB22D3009-SPE2DB25FBC93
Award Date 8/11/25
Potential Completion Date 9/2/25
Potential Value $5.2K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside, firm fixed-price delivery order carries a ceiling value of $21,489.60 and is scheduled for completion by September 29, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $18,711.54 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HYPERRAB 300 Unit/ML (1 unit). This firm fixed-price delivery order, with completion scheduled for August 28, 2025, represents a competitive award with no set-aside designation. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion...
- The Defense Logistics Agency awarded a $1,790.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside competitive award is scheduled for completion by October 6, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $17,908.00 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vial 5ML, a rabies immunoglobulin product used in post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 19, 2025, and represents a continuation of the company's ongoing pharmaceutical supply relationship with federal healthcare systems. The work will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $7,163.24 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. The contract, awarded on June 2, 2025, with an ultimate completion date of June 24, 2025, operates under a firm fixed-price structure with no set-aside designation, indicating competitive award. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child...
- On September 3, 2025, the Defense Logistics Agency awarded a delivery order valued at $4,851.14 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This firm fixed-price delivery order, with an ultimate completion date of September 24, 2025, represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HYPERRAB is a rabies immunoglobulin product used for...
- The Defense Logistics Agency issued a delivery order valued at $3,465.10 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials. This non-set-aside, firm fixed-price delivery order was awarded on July 23, 2025, with an ultimate completion date of August 13, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. HYPERRAB is a rabies immunoglobulin (human) product used for post-exposure prophylaxis and...
- This delivery order, awarded August 14, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, covers the supply of HYPERRAB 300 unit/mL vials (5 mL), a rabies immunoglobulin product critical for post-exposure prophylaxis in military and federal healthcare settings. The contract is valued at $1,790.80 with a firm fixed price structure and an ultimate completion date of September 5, 2025. The award was made through competitive procurement with no set-aside designation....
- The Defense Logistics Agency issued a delivery order valued at $1,732.55 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed price delivery order, awarded on June 25, 2025, with a completion date of July 17, 2025, represents a non-competitive procurement executed under an existing contract vehicle. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $8,954.05 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML, a rabies immunoglobulin product. This firm fixed-price delivery order, issued on August 29, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical...